SNPMiner Trials (Home Page)
Report for SNP rs11870474
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Evaluating the Effectiveness of the Use of Intravenous Infusions of Adenosine Triphosphate (ATP) in Patients With Moderate Alzheimer's Disease and Severe: Double-blind Dose Finding Clinical Trial.
To Check whether systemic treatment with ATP alters the profile of cerebral metabolism in patients with Alzheimer's disease using MRS techniques (Magnetic Resonance Spectroscopy) and adjust the infusion (minimum effective dose) that promotes this metabolic change.
NCT02279511 Alzheimer's Disease Drug: ADENOSINE TRIPHOSPHATE Drug: PLACEBO MeSH:Alzheimer Disease
HPO:Alzheimer disease
- 9. The subject or his legal representative give prior informed consent that includes genetic studies of Apolipoprotein E and rs11870474.
Primary Outcomes
Description: Spectroscopy will be taken one hour after the infusion (7h for patients allocated to 6h arm and 25h in 24h infusion arm)
Measure: Detection of brain metabolic changes after ATP infusion by spectroscopy techniques (H + MRS) Time: expected average of 7-25 hours post infusionDescription: one hour after the infusion (7h for patients allocated to 6h arm and 25h in 24h infusion arm)
Measure: Changes in Cogstate results Time: expected average of 7-25 hours post infusionSecondary Outcomes
Description: The cogstate is a software used to evaluate cognitive impairment
Measure: Changes in Cogstate results Time: 3 months compared to baseline.Measure: Changes in test Mini-Mental State Examination Time: 3 months compared to baseline.
Measure: Changes in synaptic activity after treatment administration Neurological examination Time: post treatment or 3 months post baseline
Measure: Electrocardiogram results Time: an expected average of 90 days
Measure: adverse events Time: at 90 days